



US009409990B2

(12) **United States Patent**
Zhang

(10) **Patent No.:** US 9,409,990 B2
(b4) **Date of Patent:** Aug. 9, 2016

(54) **METHODS OF INHIBITING TUMOR GROWTH BY ANTAGONIZING IL-6 RECEPTOR**

(71) Applicant: **Regeneron Pharmaceuticals, Inc.**,
Tarrytown, NY (US)

(72) Inventor: **Li Zhang**, Baldwin Place, NY (US)

(73) Assignee: **Regeneron Pharmaceuticals, Inc.**,
Tarrytown, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/329,565**

(22) Filed: **Jul. 11, 2014**

(65) **Prior Publication Data**

US 2014/0322215 A1 Oct. 30, 2014

Related U.S. Application Data

(63) Continuation of application No. 13/672,923, filed on Nov. 9, 2012, now abandoned.

(60) Provisional application No. 61/557,939, filed on Nov. 10, 2011, provisional application No. 61/609,968, filed on Mar. 13, 2012, provisional application No. 61/613,538, filed on Mar. 21, 2012.

(51) **Int. Cl.**

C07K 16/28 (2006.01)
A61K 39/395 (2006.01)
C07K 16/22 (2006.01)
C07K 19/00 (2006.01)
C07K 16/32 (2006.01)
A61K 39/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/2866** (2013.01); **A61K 39/3955** (2013.01); **A61K 39/3958** (2013.01); **C07K 16/22** (2013.01); **C07K 16/2863** (2013.01); **C07K 16/32** (2013.01); **C07K 19/00** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/507** (2013.01); **C07K 2317/73** (2013.01); **C07K 2317/76** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,480,796 A	1/1996	Kishimoto
5,670,373 A	9/1997	Kishimoto
5,795,965 A	8/1998	Tsuchiya et al.
5,817,790 A	10/1998	Tsuchiya et al.
5,888,510 A	3/1999	Kishimoto et al.
6,086,874 A	7/2000	Yoshida et al.
6,410,691 B1	6/2002	Kishimoto
7,396,664 B2	7/2008	Daly et al.
7,582,298 B2	9/2009	Stevens et al.
8,043,617 B2	10/2011	Stevens et al.
8,080,248 B2	12/2011	Radin et al.

8,183,014 B2	5/2012	Stevens et al.
8,192,741 B2	6/2012	Radin et al.
2007/0134242 A1	6/2007	Nishimoto
2007/0243189 A1	10/2007	Yoshizaki
2010/0129357 A1	5/2010	Garcia-Martinez et al.

FOREIGN PATENT DOCUMENTS

EP	1967209	6/2012
WO	2010065079	6/2010

OTHER PUBLICATIONS

Hsu et al, Biodrugs; 2009; vol. 23, No. 5, pp. 289-304.*
Agarwala and Case, "Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review," The Oncologist, Mar. 2010, 15:236-245.

Barre et al., "The STAT3 oncogene as predictive marker of drug resistance," TRENDS Mol. Med., Nov. 2006, 13 (1):4-11.

Berishaj et al., "Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer," Breast Cancer Research, May 2007, Epub 9:R32, doi: 10.1186/bcr1680.

Coward et al., "Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer," Clin. Cancer Res., Jul. 2011, 17 (18):6083-6096.
Dalwadi et al., "Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non-Small Cell Lung Cancer" Clinical Cancer Research, 2006, 11:7674-7682.

Grepin and Pages, "Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies," J. Oncology, Mar. 2010, Epub 835680, doi: 10.1155/2010/835680.

Hirata et al., "Characterization of IL-6 Receptor Expression by Monoclonal and Polyclonal Antibodies," J. Immunol., Nov. 1989, 143:2900-2906.

Hong et al., "Interleukin-6 and Its Receptor in Cancer, Implications for Translational Therapeutics," Cancer, Nov. 2007, 110(9):1911-1928.

Jain et al., "Biomarkers of response and resistance to antiangiogenic therapy" Nature Reviews Clinical Oncology (Jun. 1, 2009) 6(6):327-338.

Knupfer and Preiss, "Significance of interleukin-6 (IL-6) in breast cancer (review)," Breast Cancer Res. Treat., 2007, 102:129-135.

Mankani and Greten, "Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors," Expert Opin. Invest. Drugs, Jan. 2011, 20(9):1263-1275.

Saidi et al., "Combined Targeting of Interleukin-6 and Vascular Endothelial Growth Factor Potently Inhibits Glioma Growth and Invasiveness," Int. J. Cancer, Feb. 2009, 125:1054-1064.

(Continued)

Primary Examiner — Bridget E Bunner

Assistant Examiner — Fozia Hamud

(74) *Attorney, Agent, or Firm* — Frank Cottingham; Anna D. DiGabriele-Petti; Karl Bozicevic

(57) **ABSTRACT**

The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an IL-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-VEGF-resistant tumor in a subject. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist.